Wanbury Limited Secures Key EDQM Approval for Rivaroxaban API and Gains USFDA DMF Clearances
Wanbury Limited has achieved significant regulatory milestones, receiving crucial approvals that expand its global market reach. The company secured approval from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for its new product, Rivaroxaban API.The EDQM approval is expected to enable Wanbury Limited to meet increasing customer demand in the European Union (EU) and other countries that recognize Certified European Production (CEP).
In addition to the EU clearance, Wanbury Limited has successfully obtained DMF clearances from the U.S. Food and Drug Administration (USFDA). These clearances cover Paraxetine HCl and Metformin HCl, facilitating ANDA reviews for multiple international customers.
WANBURY Stock Price Movement
As of 2:44 PM, shares of Wanbury Limited slip downward in live trading, currently valued at ₹251.75 after shedding ₹11.00 or 4.19%. The stock traded with a volume of 359,103 shares as it continued its session movements.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.